Browsing Over 32 Presentations

Sort By
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - What options for HRD patients? Criteria for treatment choice (ID 8)

Lecture Time
15:05 - 15:25
Speakers
  • E. C. Kohn (Bethesda, United States of America)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - What options for HR proficient patients? Criteria for treatment choice (ID 9)

Lecture Time
15:25 - 15:45
Speakers
  • N. Colombo (Milan, Italy)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Clinical case - Combination vs sequence: Clinical implications (ID 10)

Lecture Time
15:45 - 16:05
Speakers
  • S. Lheureux (Toronto, Canada, Ontario)
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
1st line maintenance strategy options for advanced ovarian cancer by HRD profile Clinical case session

Live Q&A and discussion (ID 11)

Lecture Time
16:05 - 16:20
Session Name
1st line maintenance strategy options for advanced ovarian cancer by HRD profile
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Fri, 25.06.2021
Time
15:05 - 16:20
Best of abstracts session Abstract session

Long term safety and secondary efficacy end points in the ENGOT-OV16/NOVA phase 3 trial on Niraparib in recurrent ovarian cancer (ID 24)

Lecture Time
12:55 - 13:05
Speakers
  • M. Mirza (Copenhagen, Denmark)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Live Q&A and discussion (ID 25)

Lecture Time
13:15 - 13:30
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study (ID 26)

Lecture Time
13:30 - 13:40
Speakers
  • R. Kristeleit (London, United Kingdom)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) (ID 27)

Lecture Time
13:40 - 13:50
Speakers
  • K. N. Moore (Oklahoma City, United States of America, Oklahoma)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Live Q&A and discussion (ID 28)

Lecture Time
14:00 - 14:15
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Discussion (ID 33)

Lecture Time
13:50 - 14:00
Speakers
  • S. Banerjee (London, United Kingdom)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Discussion (ID 34)

Lecture Time
13:05 - 13:15
Speakers
  • E. C. Kohn (Bethesda, United States of America)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15
Best of abstracts session Abstract session

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (ID 12)

Lecture Time
12:45 - 12:55
Speakers
  • A. Poveda Velasco (Valencia, Spain)
Session Name
Best of abstracts session
Location
Channel 1, Virtual Meeting, Vienna, Austria
Date
Sat, 26.06.2021
Time
12:45 - 14:15